Administrator

Administrator

Please click the Read More link to see full results.

Please click the Read More link to view results by age group.

Vassar alumna Michelle Monje '98 talks about her work as a pediatric oncologist and her groundbreaking research on diffuse intrinsic pontine glioma, a highly aggressive pediatric brain tumor.

The Childhood Brain Tumor Foundation is thrilled to bring you two educational webcasts..

 
Medulloblastoma: A webcast presented by Dr. Roger J. Packer, Children's National Medical Center

packer

December 27, 2007

To view and listen to the webcast, first open the slide presentation (requires Microsoft Powerpoint): Medulloblastoma.ppt

Then download and play the audio file: Medullablastoma.mp3

As you hear Dr. Packer say "next slide", click on the slide presentation to advance to the next slide.

Presented by The Childhood Brain Tumor Foundation and the Children's Brain Tumor Foundation

 
Late Effects in Childhood Cancer Survivors: A webcast presented by Dr. Paul Graham Fisher, Director of the Pediatric Neuro-Oncology Clinic at Lucile Salter Packard Children's Hospital at Stanford

paul fisher Kid

January 9, 2009

To view and listen to the webcast, click on the following link:
Late effects in Childhood Cancer Survivors
(Please wait a few seconds for the webcast to begin)
 

Presented by The Childhood Brain Tumor Foundation

Children's Brain Tumor Foundation and Childhood Brain Tumor Foundation are thrilled to work collaboratively to bring you an educational webcast series..

 
Making the Diagnosis
Presented by:
Peter C. Burger, M.D.
Johns Hopkins University
School of Medicine

Peter Burger Photo copy
The following is an outline of Dr. Burger's presentation.
You may find it helpful to follow along with this document during his lecture.

[Word] [pdf]

 
Astrocytoma: New Treatment Advances
Presented by:
Roger J. Packer, M.D.
Children's National
Medical Center

Roger Packer Photo
The following is an outline of Dr. Packer's presentation.
You may find it helpful to follow along with this document during his lecture.

[Word] [pdf]


We want to hear from you!
Please complete this webinar evaluation form

Mr. James Young, one of the Founding Board Members, is the longstanding Treasurer of the Childhood Brain Tumor Foundation, Inc. His son is a long-term brain tumor survivor, diagnosed in 1991. Mr. Young is grateful that his son, Bryan, has beat the odds and remained stable with a low-grade tumor that was very diffuse at diagnosis and was expected to recur every couple of years. Mr. Young’s dedication to the Foundation has been outstanding. He lends his support to all of CBTF’s local fund-raisers and activities. Mr. Young maintains all Foundation equipment and attends closely to accounting details, reports to the Board, and provides fiscal detail that empowers the Board to make well-informed decisions. Each year, Mr. Young is the direct interface with the auditor and conveys the budget and finance outcome to the Board of Directors.

Current

Orbital Sciences Corporation – Senior Principal Aerospace Engineer

Past

Education: B.S., Electrical Engineering

Carol Cornman, Vice President of the Childhood Brain Tumor Foundation, brings her leadership skills to the organization. Each year family, friends, and supporters join Carol and her daughters in celebrating the memory of her husband Geoff Cornman, a victim of a brain tumor many years ago. Carol brings to the Childhood Brain Tumor Foundation her years of experience as one of the owners of PRISM and Vice President of Business Development. With over 18 years of experience in delivery, business development, sales, operations and executive leadership, she maintains the ability to build and execute strategic business plans and teams that are centered on quality and deliver maximum results. A focus on quality is what allows Carol to provide services which exceed customer and employee expectations. Her consultant creativity coupled with her epic business ability ensures that she is called on to master superior success with any challenge faced.

Born in New Jersey, Dr. Burger grew up in Chicago and attended Oberlin College in Ohio. His medical training began at Northwestern University Medical School in Chicago and completed at Duke University Medical Center, Durham NC after a combined residency in anatomic pathology and fellowship in neuropathology. He remained at Duke as a faculty member for twenty years until he accepted a position of Professor of Pathology, Oncology, and Neurosurgery at the Johns Hopkins University School of Medicine in Baltimore, MD.

Dr. Burger has had a special interest in brain and spinal cord tumors in children, being a reviewer of select protocols for the Children’s Oncology Group (COG), and before that for CNS tumor protocols of the Pediatric Oncology Group. Dr. Burger maintains an active consult practice as reviewer of CNS tumors, and maintains close relationships with oncology programs and pathology departments at many pediatric hospitals. While not in a position to give clinical advice, he is always willing to speak with parents about pathological issues.

Dr. Warren received her B.S., in medical technology in 1982 and her M.D., from Tufts University School of Medicine in 1990. She completed a residency in pediatrics at Children's National Medical Center, followed by a fellowship in pediatric oncology at the National Cancer Institute. She is board certified in pediatric hematology/oncology. Her research interests include performance of clinical trials, particularly in children with tumors of the central nervous system, non-invasive evaluation/imaging of the brain, and neurotoxicity resulting from tumors and their treatment.

Cancer of the central nervous system (CNS) is the leading cause of death from solid tumors in the pediatric population. For some types of CNS malignancies, such as diffuse intrinsic pontine glioma (DIPG) and recurrent malignant glioma, no significant improvement in survival has been demonstrated over the past three decades. The approach to treatment has not changed substantially, despite increasing knowledge of tumor biology. The goal of Dr. Warren's research is to establish new therapeutic paradigms based on pharmacokinetic and biologic rationale to improve both survival and quality of life for children with CNS tumors.

Dr. Warren's strategy entails a multifaceted approach.

  1. Experimental therapeutics and extensive noninvasive analysis of individual patients, including multiparametric imaging
  2. Utilization of a nonhuman primate model to study CNS pharmacology of agents and alternate delivery methods
  3. Identification of intratumor genomic alterations that encode potentially druggable targets

Click here to view Dr. Warren's full biography.

Associate Professor Pediatrics
Director, Pediatric Neuro-Oncology Program

Following his training in pediatrics, pediatric hematology-oncology and neuro-oncology, Dr. MacDonald has built a career that encompasses clinical, basic and translational research of childhood brain tumors. He has received continuous NIH-sponsored funding support for his research efforts for the past 9 years, which has focused on identification of molecular therapeutic targets of perdiatric brain tumors. Having pioneered the use of microarray technology for the study of pediatric medulloblastoma and astrocytoma, and discovering that the platelet-derived growth factor receptor (PDGFR) is active and over-produced by metastatic tumors and tumors demonstrating more malignant characteristics, respectively, he is now working to translate these and other novel findings to innovative treatments for children with brain tumors.

Before joining the Aflac Cancer Center to direct the Pediatric Neuro-Oncology Program in September 2009, Dr. MacDonald served as the Clinical Director of Neuro-oncology at Children’s National Medical Center from 1998-2009 and served as Chair of Infant Brain Tumors for the NIH-sponsored Pediatric Brain Tumor Consortium (PBTC) as well as Co-Chair of the PBTC Biology and Angiogenesis Committees since the group’s inception in 1999. In addition to serving on numerous clinical trial committees within PBTC and the Children’s Oncology Group, most prominently as Principal Investigator of the completed Phase I and currently ongoing Phase II study of cilengitide, which he helped to develop from bench-to-bedside, Dr. MacDonald was the institutional Principal Investigator for over 26 clinical trials conducted through PBTC.

One of his additional passions is training the next generation of pediatric scientists, and over the past 10 years, he has mentored 14 students, from undergraduate to graduate and medical, and 9 post-doctoral fellows, the majority of which are now currently conducting oncology research of their own.

Click here to view Dr. MacDonald's full biography.

Thanks to Our Sponsors